These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 25957808)

  • 41. Sudden cardiac death: prevention and treatment.
    Kwok KM; Lee KL; Lau CP; Tse HF
    Hong Kong Med J; 2003 Oct; 9(5):357-62. PubMed ID: 14530531
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator.
    Klein HU; Goldenberg I; Moss AJ
    Eur Heart J; 2013 Aug; 34(29):2230-42. PubMed ID: 23729691
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The implantable cardioverter-defibrillator: An update.
    Miller JD; Yousuf O; Berger RD
    Trends Cardiovasc Med; 2015 Oct; 25(7):606-11. PubMed ID: 25912255
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Wearable defibrillator.
    Schott R
    J Cardiovasc Nurs; 2002 Apr; 16(3):44-52. PubMed ID: 11958443
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sudden cardiac death in the young.
    Zeigler VL; Payne L
    Crit Care Nurs Q; 2010; 33(3):219-32. PubMed ID: 20551736
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Primary prevention of sudden cardiac death in a low-risk child with familial hypertrophic cardiomyopathy: the role of cardiac magnetic resonance imaging.
    Yamazawa H; Takeda A; Takei K; Furukawa T
    Clin Res Cardiol; 2014 Jan; 103(1):75-7. PubMed ID: 24170035
    [No Abstract]   [Full Text] [Related]  

  • 47. Can sudden cardiac death be prevented?
    Maron BJ
    Cardiovasc Pathol; 2010; 19(6):329-35. PubMed ID: 20378375
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The burden of inappropriate shocks in young people and how to avoid them.
    Upadhyay GA; Mela T; Singh JP
    Heart; 2012 Oct; 98(19):1457-66. PubMed ID: 22965797
    [No Abstract]   [Full Text] [Related]  

  • 49. The role of antiarrhythmic drug therapy for the prevention of sudden cardiac death.
    Kamath GS; Mittal S
    Prog Cardiovasc Dis; 2008; 50(6):439-48. PubMed ID: 18474286
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy.
    You JJ; Woo A; Ko DT; Cameron DA; Mihailovic A; Krahn M
    Am Heart J; 2007 Nov; 154(5):899-907. PubMed ID: 17967596
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sex differences in implantable cardioverter-defibrillator implantation indications and outcomes: lessons from the Nationwide Israeli-ICD Registry.
    Amit G; Suleiman M; Konstantino Y; Luria D; Kazatsker M; Chetboun I; Haim M; Gavrielov-Yusim N; Goldenberg I; Glikson M;
    Europace; 2014 Aug; 16(8):1175-80. PubMed ID: 24554524
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy.
    O'Mahony C; Tome-Esteban M; Lambiase PD; Pantazis A; Dickie S; McKenna WJ; Elliott PM
    Heart; 2013 Apr; 99(8):534-41. PubMed ID: 23339826
    [TBL] [Abstract][Full Text] [Related]  

  • 53. QRS Fragmentation and QTc Duration Relate to Malignant Ventricular Tachyarrhythmias and Sudden Cardiac Death in Patients with Hypertrophic Cardiomyopathy.
    Debonnaire P; Katsanos S; Joyce E; VAN DEN Brink OV; Atsma DE; Schalij MJ; Bax JJ; Delgado V; Marsan NA
    J Cardiovasc Electrophysiol; 2015 May; 26(5):547-55. PubMed ID: 25648421
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cardiac magnetic resonance for risk stratification: the sudden death risk portrayed.
    Villuendas R; Kadish AH
    Prog Cardiovasc Dis; 2008; 51(2):128-34. PubMed ID: 18774012
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The interplay between CKD, sudden cardiac death, and ventricular arrhythmias.
    Pun PH
    Adv Chronic Kidney Dis; 2014 Nov; 21(6):480-8. PubMed ID: 25443573
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prevention of sudden cardiac deaths in arrhythmogenic right ventricular cardiomyopathy: how to evaluate risk and when to implant a cardioverter-defibrillator?
    Woźniak O; Włodarska EK
    Cardiol J; 2009; 16(6):588-91. PubMed ID: 19950101
    [No Abstract]   [Full Text] [Related]  

  • 57. The need to modify patient selection to improve the benefits of implantable cardioverter-defibrillator for primary prevention of sudden death in non-ischaemic dilated cardiomyopathy.
    Disertori M; Quintarelli S; Mazzola S; Favalli V; Narula N; Arbustini E
    Europace; 2013 Dec; 15(12):1693-701. PubMed ID: 23946316
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Cardiac resynchronization therapy-always with ICD?].
    Stellbrink C
    Herz; 2005 Nov; 30(7):596-600. PubMed ID: 16333584
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Implantable defibrillators with and without resynchronization for patients with left ventricular dysfunction.
    Narayan SM
    Tex Heart Inst J; 2005; 32(3):358-61. PubMed ID: 16392218
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sudden death secondary to cardiac arrhythmias: mechanisms and treatment strategies.
    Siddiqui A; Kowey PR
    Curr Opin Cardiol; 2006 Sep; 21(5):517-25. PubMed ID: 16900017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.